Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Dengusiil in Healthy Adults
NCT04035278Phase 1Completed
- Sponsor
- Serum Institute of India
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dengue fever comparing Dengusiil with Placebo (2 arms). Primary endpoints: Solicited local and systemic reactions at 21 days, Occurrence, severity, and relatedness to vaccination of unsolicited adverse events at 21 days and 3 more. Started Dec 2019; status: completed.
02
Drugs
Dengusiil
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT04035278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04035278.